27.89
+0.57(+2.09%)
Currency In USD
| Previous Close | 27.32 |
| Open | 27.74 |
| Day High | 28.5 |
| Day Low | 27.2 |
| 52-Week High | 28.69 |
| 52-Week Low | 12.91 |
| Volume | 1.93M |
| Average Volume | 2.05M |
| Market Cap | 2.49B |
| PE | -13.81 |
| EPS | -2.02 |
| Moving Average 50 Days | 22.43 |
| Moving Average 200 Days | 19.07 |
| Change | 0.57 |
If you invested $1000 in Travere Therapeutics, Inc. (TVTX) 10 years ago, it would be worth $1,509.2 as of October 21, 2025 at a share price of $27.89. Whereas If you bought $1000 worth of Travere Therapeutics, Inc. (TVTX) shares 5 years ago, it would be worth $1,353.23 as of October 21, 2025 at a share price of $27.89.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGS
GlobeNewswire Inc.
Mar 17, 2025 11:01 AM GMT
sNDA submission based on results from Phase 3 DUPLEX and Phase 2 DUET studies of FILSPARI in FSGS If approved, FILSPARI could become the first and only FDA-approved treatment for FSGS, a rare kidney condition and a leading cause of kidney failure Add
Travere Therapeutics to Participate at Upcoming Investor Conferences
GlobeNewswire Inc.
Feb 24, 2025 9:30 PM GMT
SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will participate in the following upcoming investor conferences in March: TD Cowen 45th Annual Health Care ConferencePres
Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
GlobeNewswire Inc.
Feb 13, 2025 9:30 PM GMT
SAN DIEGO, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report fourth quarter and full year 2024 financial results on Thursday, February 20, 2025, after the close of the U.S. financial markets.